Henry Schein's Q1 2026 Results Show Momentum but Execution Risks Remain

What happened

Henry Schein reported strong Q1 2026 results, citing market share gains and gross margin expansion, building on momentum from late 2025. The company's BOLD+1 strategy continues to shift mix toward higher-margin specialty and technology segments, which now contribute over 40% of operating income. However, the DeepValue report flags ongoing restructuring charges through 2027, a leveraged balance sheet near 3x EBITDA, and a CEO transition as key risks that temper enthusiasm. While the Q1 beat is encouraging, the stock trades at ~24x P/E, modestly above a DCF estimate of $71.4, offering limited margin of safety. The thesis remains a wait-and-see until margin and FCF improvement become more durable and leadership uncertainties clear.

Implication

The Q1 results support the recovery narrative but do not yet justify upgrading to BUY. Investors should monitor margin trajectory, restructuring progress, and new CEO execution. If the company can sustain mid-single-digit growth and deleverage, the stock could re-rate higher. Conversely, any setback in restructuring or a cyber incident would raise downside risk. Maintain a neutral stance until clearer evidence of durable cash flow improvement emerges.

Thesis delta

The Q1 2026 results provide initial validation of the post-cyber recovery and BOLD+1 execution, shifting the risk/reward slightly more favorable. However, without a clear valuation discount and with execution risks still elevated, the overall judgment remains WAIT rather than BUY. The positive momentum reduces downside risk but not enough to overcome the premium valuation and uncertainties.